Krebs Biochemicals and Industries share news, announcements and annual reports
NSE: KREBSBIOBSE: 524518Pharmaceuticals & BiotechnologySmall Cap
Krebs Biochemicals and Industries Limited · Formerly Krebs Biochemicals · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1996 on NSE, May 2000 on BSE
Last close ₹56.60down ₹1.33 (2.30%)BSE ₹58.36
Share price at the NSE close on 30 Oct 2026. Previous close ₹57.93.
30 Oct: open ₹56.60, high ₹58.49, low ₹56.33
52-week range of traded prices to 30 Oct 2026
₹38.33Low, 30 Mar 2026₹76.85High, 5 Dec 2025
- Under NSE's long-term additional surveillance, stage I, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹122 Cr2,740th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Net worth zero or below
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business.
- Net worth zero or below
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −14.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- Net worth zero or below
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 5,39760.1% delivered
Krebs Biochemicals and Industries share news and announcements
498 announcements, routine notices left out, newest first. Page 10 of 10.
May 2010
24 May · Management
Board of Directors of the company in their meeting held on May 24, 2010 approved and taken a note of the Resignation of Sri. S. Prathap Kumar being Company Secretary and Compliance Officer of the company due to his inability to devote requisite time to the duties of the company due to his personal reasons.24 May · Management
Board of Directors of the company in their meeting held on May 24, 2010 approved and taken a note of the Resignation of Sri. K.S.S. Prasad, Small Share Holder Director due to his inability to devote requisite time to the affairs of the company and to discharge his duties as a Director of the company.18 May · Board meeting
To conduct the following business : (1) To take on record the minutes of the previous Board Meeting; (2) To consider and adopt the Audited Financial Statements for the year 2009-2010; (3) To consider any other business.4 May · Results
The Company's Board of Directors are considering the Audited Results for the Financial year 2009-10 instead of Un-audited Results for the last quarter of the Financial year 2009-10
Apr 2010
8 Apr · Disclosure
Disclosure under Regulation 8A(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997 as on March 31, 2010. The details of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2010
1 Feb · Reconstitution of Audit Committee
The Board of Directors of the Company in their meeting held on 27th January, 2010 Reconstituted the Audit Committee of the Company by appointing Dr.R.T.Ravi S/o Late Rama Krishnaiah Ravi as a Member of the Audit Committee of the Company. His appointment as a member is an addition to the existing members of the Audit Committee of the Company. The appointment of Dr.R.T.Ravi as a member of the Audit Committee of the Company was considered and approved and taken on record by the Board of Directors of the Company at their meeting held on Wednesday 27th January,20101 Feb · Management
The Board of Directors of the Company in their meeting held on 27th January, 2010 appointed Mr.A.V.Ravi Kumar S/o Late A.Raghava Rao as Second Nominee Director of Andhra Pradesh Industrial Development Corporation Ltd (APIDC) of the Company. Mr.A.V.Ravi Kumar is a Post Graduate in Commerce and having a qualification of D.P.A. Mr.A.V.Ravi Kumar being an Assistant General Manager of Equity Portfolio of APIDC and he is providing his services to APIDC for the last 27 years. The Co-Option of Mr.A.V.Ravi Kumar as a Director in the Board of Directors of the Company was considered and approved and taken on record by the Board of Directors of the Company at their meeting held on Wednesday 27th January,2010
Jan 2010
18 Jan · Board meeting
To conduct the following business. (1) To take on record the minutes of the previous Board Meeting. (2) To take on record the Un-Audited Financial Results for the third quarter ended as on December 31, 2009. (3) To consider any other business.
Oct 2009
20 Oct · Board meeting
To conduct the following business: 1) To take on record the Un-audited Financial Results for the Second quarter ended September, 30, 2009. 2) To consider any other business that may be brought up with the permission of the chair.
Sep 2009
16 Sep · Meeting
Outcome of Annual General Meeting of the Company held on September 14, 2009. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2009
25 Aug · Meeting
Company's Register of Members and Share Transfer Books will remain closed from September 07, 2009 to September 14, 2009 (both days inclusive) for the purpose of Annual General Meeting of the members of the Company. Further, the Company's Annual General Meeting is proposed to be held on September 14, 2009.10 Aug · Change in registered office
The company's Registered office of the company has changed with effect from 31.07.2009 according to, the decision taken by the Board as on 30.07.2009. Registered Office of the Krebs Biochemicals & Industries Ltd is shifted to 8-2-277/A, Plot No. 130, 4A, 4th Floor, Inwinex Towers, Road no. 2, Banjara Hills, Hyderabad - 500034. All the activities of the Registered Office of the Krebs Biochemicals & Industries Ltd are effectively commenced in the new premises with effect from on Friday the 31st July, 20096 Aug · Management
Board of Directors appointed Dr. R. T. Ravi Managing Director as their Chairman at their meeting held on July 30, 2009. Now onwards Dr. R. T. Ravi provides his services to the company in the post of Chairman & Managing Director (CMD).
Jul 2009
27 Jul · Board meeting
1) To take on record the un-audited financial results for the first quarter ended as on June 30, 2009, 2) To change of address of the registered office of the company with in the local limits of Hyderabad, 3) To consider any other business.
Jun 2009
15 Jun · Updates
The company Terminated its Toll Agreement with Wacker Fine Chemicals, Germany after a long period of negotiations.The agreement was entered with Wacker Fine Chemicals,Germany during the month of November,2007 is terminated
May 2009
20 May · Board meeting
To conduct the following business: (1) To take on record the Audited Financial Results for the last quarter as well as year ended March 31, 2009. (2) To consider any other business that may be brought up with the permission of the chair.
Apr 2009
13 Apr · Results
The Board of Directors of KREBS BIOCHEMICALS AND INDUSTRIES LIMITED have decided to take on record and publish the Audited Financial Results for the year ending 31st March, 2009 on or before 30th June, 2009 instead of the Unaudited Financial results for the quarter ending 31st March, 2009. Hence, no Board meeting would be convened for taking in record the Unaudited financial results for the quarter and year ended 31st March , 2009
Feb 2009
11 Feb · Disclosure
Disclosure of pledged Shares under Regulation 8A (4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation 1997 by the promoters. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements) For more details click here.2 Feb · Management
Board of Directors of the company in their meeting held on January 31, 2009 appointed Mr. Avinash Ravi S/o Dr. R. T. Ravi as Additional Director of the company w.e.f. February 1, 2009. Mr. Avinash Ravi S/o R. T. Ravi was servicing with the company for the last few months in the post of Chief operating Officer. The Board felt that the same person could give much more services to the Board after his appointment as an Additional Director to lead the company in such a way that the company will utilize its optimum capacity and resources. The Same was approved in the board meeting and taken on record by the Board of Directors of the company at their meeting held on January 31, 2009.
Jan 2009
27 Jan · Management
Mr. S. Prathap Kumar being a member of the institute of Company Secretary of India appointed as a company secretary of the company pursuant to section 383A(1) of the Companies Act,1956 read with the Companies ( Appointment and Qualification of Secretary ) Rules, 1988 wef November 01, 2008.20 Jan · Board meeting
To conduct the following business: 1) To take on record the Unaudited Financial Results for the third quarter ended December 31, 2008. 2) To consider any other business that may be brought up with the permission of the chair.
Oct 2008
24 Oct · Board meeting
Inter alia to consider and approve Unaudited Financial Results for the quarter ended September 30, 2008.3 Oct · Allotment of Equity Shares
Warrants Committee in its meeting held on September 19, 2008 has allotted 20,00,000 Equity shares to the following investors, consequent to the conversion of 20,00,000 Warrants issued on March 21, 2008. The conversion of warrants into Equity shares was done subsequent to the receipt of the balance money for the conversion: List of Allottees: 1) Mr. Aditya Ravi - 12,20,000; 2) Mr. Ajay Ravi - 4,00,000; 3) Dr. T Kuchroo - 50,000; 4) Mr. G V L Prasad - 1,00,000; 5) Mr. Murthy Raju - 80,000; 6) Mr. B H Naga Raju - 80,000; 7) Mr. K Venkateswarlu - 70,000. Total: 20,00,000.
Sep 2008
24 Sep · Meeting
Outcome of Annual General Meeting of the Company held on September 24, 2008. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.1 Sep · Meeting
Annual General Meeting of the company will be held on September 24, 2008 and the register of Members and share transfer Registers will remain closed from September 17, 2008 to September 24, 2008 both days inclusive.
Jul 2008
21 Jul · Change in Board of Directors
IDBI have nominated Mr. S. Ganesh as director of this company, in place of Dr. B. Brahmaiah with effect from 7-5-2008. Dr. Brahmaiah ceases to be director with effect from that date Mr. S. Ganesh is the Asst. General Manager, IDBI Bank, Hyderabad17 Jul · Board meeting
To consider and take on record- (1) The unaudited financials results of the company for the first quarter of the year 2008-2009 ended June 30, 2008 and (2) The audited accounts for the year 2007-2008 ended March 31, 2008.
Apr 2008
21 Apr · Board meeting
To consider and take on record the unaudited financial statements for the 4th quarter ended March 31, 2008 and for the year ended on that date.7 Apr · Updates
As known to you the company is running in losses for the preceding three years and finding it difficult to meet the schedule of payment of installments on term loans in time. To overcome the situation, the company decided to approach the Corporate Debt Restructuring (CDR) Cell with a request to rearrange the loan repayments and reduce immediate liability. In their meeting held on 5-3-2008, the Empowered Group of the CDR Cell considered and approved the following proposals : 1) Reduction of interest rate on terms loans to 9% per annum; 2) Reduction of interest rate on working capital to 8.5% per annum; 3) Conversion of 50% of working capital limits as on 1-10-2007 as working capital term Loan; 4) Funding of interest on WCTL/FITL/TL from 1-10-2007 to 31-3-2009 at 9% p.a.; 5) Repayment of WCTL/FITL/TL in 20 installments commencing from 1-4-2010; 6) Sale of assets of the Food Division of the company
Jan 2008
22 Jan · Updates
In the meeting held on January 22, 2008, the Board of Directors approved the manufacturing contract with M/s Wacker Chemie AG of Munich, Federal Republic of Germany. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Jan · Board meeting
To consider and take on record the unaudited financial results for the third quarter and nine months ended December 31, 2007.
Oct 2007
16 Oct · Board meeting
Meeting on 24 Oct 2007: “Unaudited Results for Qtr & Half year ended Sep 30, 2007”9 Oct · Meeting
Proceedings of the Annual General Meeting of the Company held on September 27, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Oct · Meeting
Outcome of the Annual General Meeting of the company held on September 27, 2007. The details of the business transacted at the AGM shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2007
5 Sep · Corporate action
Krebs Biochemicals Ltd had informed the Exchange that the Annual General Meeting of the Company will be held on September 27, 2007 and the Register of Members and the Share Transfer Registers will remain closed from September 21, 2007 to September 29, 2007 both days inclusive. Now the Company has informed the Exchange that "The dates of closure of registers as from 21-9-2007 to 27-9-2007 and not 29th September, 2007".
Aug 2007
29 Aug · Meeting
Annual General Meeting of the Company will be held on September 27, 2007 and the Register of Members and the Share Transfer Registers will remain closed from September 21, 2007 to September 29, 2007 both days inclusive.
Jul 2007
17 Jul · Board meeting
Meeting on 27 Jul 2007: “Unaudited financial results for quarter ended June 30, 2007”
May 2007
25 May · Board meeting
Inter-alia to consider and take on record Audited Financial Results for the Fourth quarter and audited results for the year ended March 31, 2007.
Mar 2007
21 Mar · Board meeting
The committee constituted by the board for the purpose of allotment of warrants met at the registered office on 21-3-2007 and allotted the warrants as follows: 1) Dr.R.T.Ravi (HUF) - 12,20,000; 2) Mr. Ajay Ravi - 4,00,000; 3) Dr. T.Kuchroo - 50,000; 4) Mr. G.V.L.Prasad - 1,00,000; 5) Mr. G.Murthy Raju - 80,000; 6) Mr. Bh.Nagaraju - 80,000; 7) Mr. K. Venkateswarlu - 70,000. Total - 20,00,000. The above allotment is subject to the condition that the allottees pay the balance amount of 90% due on the value of shares within a period of 18 months from 21-3-2007 (the date of allotment of warrants) and get them converted into equal number of equity shares in the company and also subject to the regulations of SEBI applicable to preferential allotments14 Mar · Board meeting
The empowered committee of directors will be meeting at 11.00 a.m. on Wednesday 21st March, 2007 to allot the warrants to the selected persons as given in the special resolution passed by the members in the extraordinary general meeting.14 Mar · Allotment of Warrants
In the meeting held on 22-2-2007 the Board of Directors decided to constitute a committee of Directors for allotment of warrants as approved by the members in the extraordinary general meeting held on 7-2-2007. The committee is authorized to allot the warrants subject to approval of the stock exchanges and complying with other regulations in force and to consider and approve conversion of warrants into equity shares as and when the conditions are satisfied.9 Mar · E-mail ID for Investor Complaints
We have opened an e-mail ID as follows: Inv_complnt@krebsbiochem.com. It is exclusively for investors to register their complaints
Feb 2007
22 Feb · Board meeting
Board of directors, in their meeting held on February 22, 2007, have allotted 10,50,000 equity shares to M/s. Ranbaxy Laboratories Ltd., on preferential basis.22 Feb · Management
In the meeting held on 22-2-2007, the board of directors appointed Dr. Naresh Kumar, Senior Vice President, Ranbaxy Laboratories Ltd., as an additional director on the board of M/s Krebs Biochemicals and Industries Ltd.14 Feb · Board meeting
In pursuance of the sanction given by the members in the extraordinary general meeting held on 7-2-2007 and having received the in-principle approval from the Bombay stock Exchange Ltd., the Board of directors will be meeting on Thursday 22nd February, 2007 to consider and allot the 10,50,000 equity shares on preferential basis to M/s Ranbaxy Laboratories Ltd".
Jan 2007
25 Jan · Meeting
Notice of the Extraordinary General Meeting of the Shareholders of the Company which will be held on February 07, 2007". The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Jan · Business
"The board of directors, in the meeting held on 15-1-2007 approved the issue of 10,50,000 equity shares on preferential basis to M/s Ranbaxy Laboratories Ltd. at a price of Rs.85/- per share (Including Rs.10 nominal value and Rs.75/- premium). The board has also approved issue of 20,00,000 warrants to promoter group and selected investors on preferential basis to be converted to 20,00,000 equity shares at a price of Rs. 74.30 within a period of 18 months from the date of allotment. The approvals of the board are subject to regulations of SEBI (Disclosure and Investor Protection) Guidelines, 2000". Further, the copies of the shareholding pattern after allotment of the shares on preferential basis (Table - 1) & the shareholding pattern after the warrants are converted into equity shares (Table - 2) shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 Jan · Board meeting
To consider and take on record the unaudited financial results for the quarter ended 31st December, 2006. The Board will also consider allotment of equity shares and warrants to promoters and others on preferential basis subject to SEBI Regulations.